NCT05768932 2025-10-15BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid LeukemiaSillaJen, Inc.Phase 1 Recruiting260 enrolled
NCT06536959 2024-08-05VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDSBeijing 302 HospitalPhase 2 Recruiting67 enrolled